Anastrozole

Key facts

Invented name
Arimidex and associated names
Active substance
Anastrozole
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/20/2009
PIP number
Anastrozole
Pharmaceutical form(s)
Tablets
Condition(s) / indication(s)
  • Short stature due to Growth Hormone deficiency
  • Testotoxicosis
  • McCune-Albright syndrome
  • Gynaecomastia
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB (UK)

Tel. +44 2037496236
E-mail: paediatrics@astrazeneca.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Compliance procedure number
EMEA-C-000283-PIP01-08
Compliance opinion date
03/04/2009
Compliance outcome
positive

Decision

Topics

How useful was this page?

Add your rating